The FDA has approved brentuximab vedotin (Adcetris, Seagen) for the treatment of pediatric patients aged 2 years and older with previously untreated high-risk classic Hodgkin lymphoma (HL), in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide.
The approval is based on data from a phase 3 study (AHOD1331) conducted by the Children’s Oncology Group and funded by the National Cancer Institute that showed patients receiving brentuximab vedotin in
NOVEMBER 16, 2022